









市場行情
/
股票
/
nasdaq-phvs
/

Pharvaris NV

PHVS

25.630USD

-0.370-1.42%

收盤 01/14, 16:00（美東）報價延遲15分鐘

1.66B總市值

虧損本益比TTM



Pharvaris NV

25.630

-0.370-1.42%

概覽公司財務分析

概覽

公司

財務

分析

關於 Pharvaris NV 公司

Pharvaris NV is a Netherlands-based company primarily engaged in the biopharmaceutical industry. The Company focuses on developing oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks. Their key product is Deucrictibant (PHA121, PHA-022121), which is a small-molecule bradykinin B2 receptor antagonist. It is intended for both the on-demand and prophylactic treatment of HAE attacks. Deucrictibant has been studied in vitro, ex vivo, and in vivo models to assess its effectiveness in blocking the bradykinin B2 receptor. The Company is developing deucrictibant for on-demand use as PHVS416, a softgel capsule, and for prophylactic use as PHVS719, an extended-release tablet.

Pharvaris NV簡介



公司代碼PHVS

公司名稱Pharvaris NV

上市日期Feb 05, 2021

CEOModig (Berndt B.A.E)

員工數量- -

證券類型Ordinary Share

年結日Feb 05

公司地址Emmy Noetherweg 2

城市LEIDEN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Netherlands

郵編2333 BK

電話31712036410

網址https://pharvaris.com/

公司代碼PHVS

上市日期Feb 05, 2021

CEOModig (Berndt B.A.E)

Pharvaris NV公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.48M

-26250.00%

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-18897.00%

Ms. Viviane Monges

Non-Executive Director

54.91K

+23186.00%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+318.00%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+28436.00%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

+800.00%

Dr. Jochen Knolle, Ph.D.

Co-Founder, Chief Operating Officer, Chief Scientific Officer

Dr. Peng Lu, M.D., Ph.D.

Chief Medical Officer

Dr. Anne Lesage, Ph.D.

Co-Founder, Chief Early Development Officer

Dr. Morgan Conn, Ph.D.

Chief Business Officer

名稱

名稱/職務

職務

持股

持股變動

Mr. Berndt Modig, CPA

Chief Executive Officer, Co-Founder, Executive Director

1.48M

-26250.00%

Dr. David P. Meeker ,M.D.

Non-Executive Director

102.82K

-18897.00%

Ms. Viviane Monges

Non-Executive Director

54.91K

+23186.00%

Ms. Anna Nijdam

Head of Finance, Principal Accounting Officer

50.54K

+318.00%

Dr. Elisabeth Bjork, M.D., Ph.D.

Non-Executive Director

50.53K

+28436.00%

Mr. David W. Nassif, J.D.

Chief Financial Officer

800.00

+800.00%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

General Atlantic LLC

12.54%

Fidelity Management & Research Company LLC

9.99%

Foresite Capital Management, LLC

7.46%

VenBio Partners LLC

7.24%

Viking Global Investors LP

5.70%

其他

57.07%

持股股東

佔比

General Atlantic LLC

12.54%

Fidelity Management & Research Company LLC

9.99%

Foresite Capital Management, LLC

7.46%

VenBio Partners LLC

7.24%

Viking Global Investors LP

5.70%

其他

57.07%

股東類型

持股股東

佔比

Private Equity

33.13%

Hedge Fund

22.83%

Investment Advisor

18.10%

Venture Capital

11.99%

Investment Advisor/Hedge Fund

9.82%

Individual Investor

5.32%

Research Firm

0.17%

Bank and Trust

0.07%

Pension Fund

0.05%

機構持股



更新時間: 1月1日週四

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

140

61.63M

96.21%

+11.08M

2025Q3

118

49.64M

77.50%

-950.63K

2025Q2

125

52.21M

81.51%

-1.38M

2025Q1

125

53.89M

99.06%

+200.61K

2024Q4

123

53.45M

98.98%

+218.03K

2024Q3

114

53.86M

99.73%

+1.03M

2024Q2

52.08M

96.43%

-141.66K

2024Q1

49.63M

98.30%

-831.88K

2023Q4

47.76M

94.74%

+8.60M

2023Q3

36.05M

91.51%

-2.92M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

General Atlantic LLC

8.03M

12.54%

+500.00K

+6.64%

Sep 30, 2025

Fidelity Management & Research Company LLC

6.40M

9.99%

+976.76K

+18.01%

Sep 30, 2025

Foresite Capital Management, LLC

4.78M

7.46%

+368.00K

+8.34%

Sep 30, 2025

VenBio Partners LLC

4.64M

7.24%

+350.00K

+8.16%

Sep 30, 2025

Viking Global Investors LP

3.65M

5.7%

Sep 30, 2025

EQT Life Sciences

3.56M

5.55%

Apr 01, 2025

EQT Partners AB

3.42M

5.35%

+3.42M

Sep 30, 2025

Bain Capital Life Sciences Investors, LLC

3.18M

4.97%

-122.11K

-3.70%

Sep 30, 2025

Deerfield Management Company, L.P.

2.44M

3.81%

+425.00K

+21.07%

Sep 30, 2025

Commodore Capital LP

2.42M

3.78%

+507.04K

+26.53%

Sep 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Virtus LifeSci Biotech Clinical Trials ETF

0.87%

ALPS Medical Breakthroughs ETF

0.59%

iShares MSCI Netherlands ETF

0.23%

SPDR S&P International Small Cap ETF

0.08%

iShares MSCI Europe Small-Cap ETF

0.04%

iShares MSCI EAFE Small-Cap ETF

0.02%

Fidelity Nasdaq Composite Index ETF

0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

0.01%

Avantis International Small Cap Equity ETF

First Trust IPOX Europe Equity Opportunities ETF

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.87%

ALPS Medical Breakthroughs ETF

佔比0.59%

iShares MSCI Netherlands ETF

佔比0.23%

SPDR S&P International Small Cap ETF

佔比0.08%

iShares MSCI Europe Small-Cap ETF

佔比0.04%

iShares MSCI EAFE Small-Cap ETF

佔比0.02%

Fidelity Nasdaq Composite Index ETF

佔比0.01%

Xtrackers MSCI Eurozone Hedged Eqty ETF

佔比0.01%

Avantis International Small Cap Equity ETF

佔比0%

First Trust IPOX Europe Equity Opportunities ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

除權除息日

類型

比率

暫無數據

公告日期

除權除息日

類型

比率

暫無數據

常見問題

Pharvaris NV的前五大股東是誰？



Pharvaris NV的前五大股東如下：
General Atlantic LLC
持有股份：8.03M
佔總股份比例：12.54%。
Fidelity Management & Research Company LLC
持有股份：6.40M
佔總股份比例：9.99%。
Foresite Capital Management, LLC
持有股份：4.78M
佔總股份比例：7.46%。
VenBio Partners LLC
持有股份：4.64M
佔總股份比例：7.24%。
Viking Global Investors LP
持有股份：3.65M
佔總股份比例：5.70%。